Protocol 20130287
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate safety, tolerability, and efficacy of evolocumab (AMG 145) on LDL-C in subjects with Type 2 Diabetes Mellitus and hypercholesterolemia/mixed dyslipidemia on maximally tolerated statin therapy.
The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in subjects with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral dose of statin of at least
moderate-intensity.
Learn More
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Menu
Newsletter
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.
Thanks for subscribing! Please check your email for further instructions to confirm your subscription.